Charles River Laboratories agreed to buy the remaining 79% of PathoQuest and the assets of K.F. (Cambodia), strengthening its NGS‑based biologics QC capabilities and securing nonhuman primate (NHP) supply. The PathoQuest purchase (~$60M) adds NGS viral‑safety testing solutions; the K.F. acquisition (~$510M) expands CRL’s captive NHP supply chain for toxicology and discovery work. CRL positions these deals as a dual strategy: invest in new‑approach NGS QC methods that can reduce animal use while simultaneously securing traditional in vivo resources to stabilize clients’ development pipelines and mitigate supply risks in biologics testing.